Disposal of donor livers in Brazil: how to optimize their utilization rate in transplants?

Drezza, Júlia Porto de Oliveira; Boteon, Amanda Pinter Carvalheiro da Silva; Calil, Igor Lepski; Anna, Raoni Salomão Sant; Viveiros, Marcelo de Melo; Rezende, Marcelo Bruno de; Pecora, Rafael Antônio Arruda; Boteon, Yuri L.

doi:10.31744/einstein_journal/2021ao6770

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other countries with a large population, including Brazil, China, and India, will enormously benefit from dynamic preservation techniques, provided that the technology achieves cost-effectiveness. Based on an often not standardized and suboptimal donor management (ie, treatment of central diabetes insipidus correcting for hypernatremia, lack of infectious disease screening, hemodynamic stabilization) frequently seen in such countries, the majority of donor's livers would classify as marginal and may benefit from MP and viability assessment 52 . The reason behind this is often the lack of official guidelines and center support provided by the national governing bodies of organ transplantation.…”

Section: What Is the Potential Market?mentioning

confidence: 99%

Obstacles to implement machine perfusion technology in routine clinical practice of transplantation: Why are we not there yet?

et al. 2023

Self Cite

View full text Add to dashboard Cite

Machine perfusion of solid human organs is an old technique, and the basic principles were presented as early as 1855 by Claude Barnard. More than 50 years ago, the first perfusion system was used in clinical kidney transplantation. Despite the well-known benefits of dynamic organ preservation and significant medical and technical development in the last decades, perfusion devices are still not in routine use. This article describes the various challenges to implement this technology in practice, critically analyzing the role of all involved stakeholders, including clinicians, hospitals, regulatory, and industry, on the background of regional differences worldwide. The clinical need for this technology is discussed first, followed by the current status of research and the impact of costs and regulations.Considering the need for strong collaborations between clinical users, regulatory bodies, and industry, integrated road maps and pathways required to achieve a wider implementation are presented. The role of research development, clear regulatory pathways, and the need for more

show abstract

Section: What Is the Potential Market?mentioning

confidence: 99%